CYAD 02
Alternative Names: CYAD-02Latest Information Update: 04 Apr 2023
At a glance
- Originator Dartmouth College
- Developer Celyad Oncology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 02 Mar 2023 Phase I development is ongoing the US and Belgium(NCT04167696)
- 31 Dec 2022 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in Belgium, USA (Parenteral), prior to December 2022
- 31 Dec 2022 Discontinued - Phase-I for Myelodysplastic syndromes (Second-line therapy or greater) in Belgium, USA (Parenteral), prior to December 2022